Organon vs Zoetis
Zoetis reported revenue of $9.5 billion in fiscal 2025, 1.5 times Organon's $6.2 billion in fiscal 2025. Organon's revenue fell 2.9% in its latest year, and Zoetis' grew 2.3%. Free cash flow was $538 million at Organon and $2.3 billion at Zoetis.
Side by side
| Organon | Zoetis | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6.2B | $9.5B |
| Revenue growth | −2.9% | 2.3% |
| Revenue growth a year, last 5 years | −1.0% | 7.2% |
| Gross margin | 53.3% | 71.8% |
| Operating margin | — | — |
| Net margin | 3.0% | 28.2% |
| Free cash flow | $538M | $2.3B |
| Free cash flow margin | 8.7% | 24.1% |
| Return on capital | 5.3% | 29.3% |
| Net debt to EBITDA | 6.3x | 1.7x |
| Dividends and buybacks | $88M | $4.1B |
| Change in diluted share count | 0.6% | −2.4% |
| Last close | $13.74 | $80.97 |
| P/E at the last close | 17.6× | 13.3× |
| Insider trades, last 12 months | bought $854,704, sold $200,307 | bought $886,384, sold $2.5 million |
| Piotroski F-score | 5 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
OrganonZoetis
Operating margin
Percent of revenue
OrganonZoetis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
OrganonZoetis